MAP2K7 and neoplasm: Dormancy, a slow-cycling, persistent quiescent state, allows cells to survive in a hostile tumor microenvironment under treatment pressure such as RAS/RAF/MEK inhibitors, which serves as a likely reservoir for the emergence of fully resistant proliferative cells [80–82].